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1. Introduction 
In recent years, important advances have been made in the medical therapy of metastatic 
renal cell carcinoma (mRCC). These advances are due on the one hand to the availability of 
many new molecules directed at specific biomolecular targets, and on the other hand to the 
understanding of both the pathogenetic mechanisms which have led to the identification of 
the key role of some gene mutations and angiogenesis, fundamental mechanisms in the 
process of tumour proliferation (1,2). In particular, there have been great developments in 
molecules capable of inhibiting the activity of the pro-angiogenesis receptors of vascular 
endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) such as 
tyrosine-kinase inhibitors (TKI) sunitinib, sorafenib, pazopanib, and monoclonal antibodies 
bevacizumab. Also inhibitors of specific pathways correlated with tumour growth such as 
the mTOR inhibitors temsirolinmus and everolimus have become crucial drugs in the 
management of mRCC (3). 
In the last few years, these drugs have radically changed the course of medical therapy of 
mRCC and other molecules currently in an advanced stage of clinical development will soon 
further enrich the therapeutic options of mRCC: axitinib (new, powerful anti-tyrosine 
kinases inhibitor), dovitinib (multi-target inhibitor particularly active against Beta Fibroblast 
Growth Factor Receptor (FGFR)), volociximab (new chimeric antibody with powerful anti-
angiogenic activity directed towards the ┙5┚1integrin), regorafenib, cediranib etc. 
As is known, RCC is a highly vascularized neoplasm which is dependent on VEGF-
mediated angiogenesis. In fact, mRCC is among neoplasms showing the highest level of 
circulating VEGF. The importance of VEGF signaling for tumoral growth is also supported 
by the high frequency of von Hippel-Lindau (VHL) gene mutations found in about 70% of 
clear cell RCC. The VHL gene product regulates VEGF expression through suppression of 
the HIF transcription factor. Loss of function mutations in VHL lead to unregulated 
activation of HIF and overexpression of VEGF and other proangiogenic factors. For these 
reasons, anti-angiogenic drugs are particularly active in clear cell RCC and these drugs are 
currently considered the standard of care for first-line treatment. They include the 
monoclonal antibody bevacizumab which binds to the soluble ligand of VEGF, and the 
inhibitors of multiple receptor TK for vascular endothelial growth factor receptors (VEGFR-
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1, VEGFR-2, and VEGFR-3), PDGFR-┙ and PDGFR-┚, FLT3, the stem cell growth factor 
receptor KIT, and RET (4). 
Despite the efficacy of TKI and bevacizumab therapy, the development of resistance is of 
major clinical concern; in fact, almost all patients with mRCC develop resistance and the 
disease inexorably progress.  
Conventionally, patients are categorised as “early progressors” when they develop 
resistance within approximately 6 months of the beginning of first-line therapy, and “late 
progressors” when they develop resistance later. About  30% of patients present a primary 
resistance to these drugs with a rapid spreading of disease and a very poor survival 
(primary refractory). Another  40% of patients, after an initial positive response, exhibit 
disease progression after about 1 year of treatment (5).  
Consequently, the number of patients who receive a second line therapy after anti-
angiogenic agents is only about half of the total. In the registrative phase III trial which 
compared sunitinib to interferon alpha, of 375 patients treated in the sunitinib arm, only 182 
patients, corresponding to 56% of the total, received a second line therapy with an anti-
mTOR or with a second anti-angiogenic drug (6). Similarly, in the AVOREN study with 
bevacizumab plus interferon vs interferon alone, of 325 patients in the bevacizumab plus 
interferon arm only 180 patients corresponding to 55% received a second line therapy (7). 
These data have been confirmed in the similar CALGB 90206 study (8). Notably, outside 
large controlled studies the percentage of patients receiving a second line treatment after 
anti-angiogenic agents is much lower. In a recent retrospective analysis of 645 patients from 
7 centers and recruited in various studies, only 216 (30%) underwent second line therapy 
with anti-VEGF/anti-mammalian target of rapamycin (mTOR) drugs (9). Of interest, basal 
performance status resulted the only significant independent predictor of receiving second-
line targeted therapy. Moreover, patients who received a second-line anti-VEGF drug 
appeared to have a similar overall survival to those who receive a second-line anti-mTOR 
drug (9). 
The adoption of alternative angiogenic signaling pathways to compensate for inhibition of 
VEGF/VEGFR-mediated signaling seems to be the main, but not the only, common 
mechanism for the development of cancer resistance to VEGF pathway inhibitors. 
Nevertheless, to date very few data are available in literature about which alternative 
pathways are involved in resistant disease. Therefore, understanding the escape 
mechanisms of resistance to anti-angiogenic agents could improve clinical outcomes and the 
number of responsive patients. 
2. Mechanisms of resistance in MRC 
Resistance is generally defined as the capability of tumors to evade the antineoplastic effects of 
various treatments. About 30% of mRCC have an innate resistance to all available treatments 
independently from the type of anti-angiogenic agent used. Furthermore, treatment with 
mTORi as second line therapy results in primary resistance in about 20% of patients. 
In this chapter we will attempt to give some partial responses to the numerous questions 
regarding the significance of resistance in mRCC: what is the definition of resistance? Which 
mechanisms sustain it? How can we overcome the resistance mechanisms?  
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2.1 Definition of resistance and its clinical implications 
Resistance is divided into primary (also “refractoriness” or “intrinsic responsiveness”), 
which is characterized by a lack of efficacy to anti-angiogenic agents from the start of 
therapy, and secondary (also “acquired” or “adaptive” or “evasive” or “angiogenesis 
escape”), which begins after an initial response to TKI lasting for a period of time of variable 
length. Notably, early treatment failure involves all anti-angiogenic agents and all type of 
patients with mRCC.  
Nevertheless, primary resistance to TKI in mRCC is heavily influenced by the patient risk 
score (low-intermediate vs poor) and by the type of first line therapy used. Primary 
refractory patients are about 20% in good-intermediate risk patients treated with different 
TKI, and it arises over 30% in poor risk patients (6, 8, 10, 11). In addition, the mTORi 
everolimus generally utilized as second line therapy is characterized by a resistance 
involving about 20% of patients (12). It is not clear if the patients who present primary 
resistance are the same as those who also present secondary resistance as data on this topic 
are not available. 
The influence of prior therapies on the risk of primary resistance in patients with mRCC 
treated with sunitinib as first line has recently been reported in a systemic review and meta-
analysis of 10 clinical studies including a total of 4,320 (13). The overall incidence of primary 
resistance to sunitinib was 22.4%. Moreover, the risk of developing primary resistance was 
significantly lower in patients with clear-cell cancer compared with non-clear-cell cancer. 
Notably, patients with prior cytokine therapy exhibited a significantly higher risk of primary 
progressive disease with sunitinib compared with those who had no prior treatment (RR, 1.18, 
95% CI, 1.05-1.34, p=0.007). Although not statistically significant, there was a trend supporting 
that prior treatment with another mTKI sorafenib increased the risk of resistance to sunitinib 
in comparison with no prior treatment (RR 1.33, 95% CI: 0.98-1.80, p=0.069).  
The conclusions of the Authors are that the risk of primary resistance to sunitinib may vary 
with tumor histology and prior therapies. In particular, previous exposure to cytokines 
significantly increased the risk of primary resistance suggesting that an immune mechanism 
may underlie the resistance to this drug.  
A similar meta-analysis was done in patients treated with sorafenib as first line therapy (14). 
A total of 3,269 patients from 20 studies were included for the analysis. The overall 
incidence of primary resistance was 22.6% without significant difference between clear cell 
and non-clear cell nor between prior cytokine therapies and no prior treatment. Notably, 
patients with prior exposure to sunitinib had a significantly higher incidence of resistance 
when treated with sorafenib (52.2%). The conclusions of the Authors are that prior exposure 
to sunitinib but not cytokines significantly increased the risk of resistance with sorafenib in 
mRCC patients, suggesting that initial therapy with angiogenesis inhibitors may promote 
the development of resistance to sorafenib.  
The conclusive considerations regarding the primary resistance to anti-angiogenic agents in 
mRCC are that about 30% of mRCC have an innate resistance to all available treatments and 
the resistance to angiogenic drugs seems to be independent from the type of TKI used.  
In second line treatment, resistance to mTORi everolimus occurs in about 20% of patients 
(12), but when a second TKI was used, the risk of resistance increased to about 50%. 
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Therefore, considering that only 30%-50% of patients receive second line therapy, the re-
challenge with a second TKI is an option available for very few and selected  patients.  
2.2 The resistance mechanisms 
Resistance has yet to be thoroughly understood in kidney cancer. The “angiogenic escape” 
to anti-VEGF treatment may be dependent both on cancer cell phenomena or endothelial 
cell phenomena. It is believed that multiple factors affect resistance including factors that 
decrease angiogenesis and factors that increase angiogenesis. Often these mechanisms are 
present contemporarily in a single patient. Several of these factors need to be accounted for 
when developing a comprehensive treatment approach and in understanding why a patient 
may be resistant to any one approach. 
Hypoxia is a known inducer of angiogenic response in a wide variety of tumors. 
Nevertheless, it is strongly believed that hypoxia is also the key mechanism of angiogenic 
escape. It involves induction of gene expression via HIF transcription factor of various pro-
angiogenic factors including VEGF, FGFs and ephrins. When angiogenesis is inhibited, 
tumors are in a hypoxic state and develop new alternative pathways to guarantee their 
further growth (15).  
2.3 Primary resistance mechanisms 
It is thought that patients with primary resistance to TKI have already activated one or more 
alternative mechanisms of resistance in response to the selective pressure of their 
microenvironment. Probably these cases are not, or not only, sustained by angiogenesis 
mechanisms. Moreover, in patients with primary resistance there is frequently an 
upregulation of alternative pro-angiogenic pathways mediated by FGFR, interleukin-8 (IL-
8), insulin-like GFR, ephrins, and angiopoietins. In particular, FGF/FGFR system has been 
reported as one of the most important escape pathways of anti-VEGFR therapies.  
Other possible mechanisms include the pre-existing inflammatory cell-mediated vascular 
protection (myeloid cell); an hypovascularity status with consequent indifference toward 
angiogenesis inhibitors (desmoplastic stroma); the co-option of normal vessels without 
requisite angiogenesis (4, 16-18). 
2.4 Secondary resistance mechanisms 
Regarding secondary resistance, many Authors believe that it is precisely the state of 
hypoxia determined by anti-angiogenic drugs which is at the root of the onset of the escape 
mechanisms sustained by new HIF, FGF, IL-8, ephrine etc transcript factors, which lead to 
the activation of alternative pathways which support a “new angiogenic wave” (15). It is 
notable that during therapy with anti-VEGF the expression of new and ever-increasing pro-
angiogenic factors is observed. It is known that the early phase of angiogenesis is generally 
characterized by a response to anti-VEGF treatment. On the contrary, the late phase of 
angiogenesis is characterized by the escape to anti-VEGF treatment. This late phase is 
sustained by FGF, IL-8 and other factors. It has been reported that in the presence of 
sunitinib the tumor is able to produce until 19 pro-angiogenic factors to rescue endothelia 
cell proliferation (19,20). 
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Function-blocking antibodies to VEGF receptors R1 and R2 were used to probe their roles in 
controlling angiogenesis in a mouse model of pancreatic islet carcinogenesis. Inhibition of 
VEGFR2 but not VEGFR1 markedly disrupted angiogenic switching, persistent 
angiogenesis, and initial tumor growth. In late-stage tumors, phenotypic resistance to 
VEGFR2 blockade emerged, as tumors regrew during treatment after an initial period of 
growth suppression. This resistance to VEGF blockade involves reactivation of tumor 
angiogenesis, independent of VEGF and associated with hypoxia-mediated induction of 
other proangiogenic factors, including members of the FGF family. These other 
proangiogenic signals are functionally implicated in the revascularization and regrowth of 
tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF 
inhibition (15). 
Recently, it has been demonstrated that the FGF pathway is important in patients who 
develop resistance to sunitinib. Welti and collegues (21) reported that FGF2 supports 
endothelial proliferation and de novo tubule formation in the presence of sunitinib and that 
FGF2 can suppress sunitinib-induced retraction of tubules. Importantly, these effects of 
FGF2 were ablated by PD173074, a small molecule inhibitor of FGF receptor signalling. They 
also showed that FGF2 can stimulate pro-angiogenic signalling pathways in endothelial cells 
despite the presence of sunitinib. Finally, analysis of clinical renal-cancer samples 
demonstrated that a large proportion of renal cancers strongly express FGF2. In conclusion, 
they suggest that therapeutic strategies designed to simultaneously target both VEGF and 
FGF2 signalling may prove more efficacious than sunitinib in renal cancer patients whose 
tumours express FGF2. 
Interestingly, it has been demonstrated that FGFR is highly expressed in RCC. Tsimafeyeu 
and collegues analyzed the expression of FGFR1 in 140 patients with mRCC. Expression of 
FGFR1 was observed in 98% of primary tumors and in 82.5% of lymph node metastases. 
Moreover, a significant rise in plasma bFGF levels was reported in patients with disease 
progression but a non-significant fall in patients with response or stable disease. Plasma 
VEGF-A level increased in patients with response whereas  no detectable changes in plasma 
VEGF-A level was found in patients with progressive disease. The conclusions of the 
Authors are that plasma levels of bFGF and VEGF-A are altered in MRCC patients receiving 
sunitinib, and the increases in bFGF levels may represent biomarker of resistance to targeted 
therapy (22). Recently it has confirmed that the subset of clear cell RCC tumors with 
increased expression of FGFR1 is associated with a shorter progression free survival (23). 
Also the role of IL-8 in resistance mechanisms seems to be determinant. In xenograft models, 
sunitinib resistance/refractoriness has been reported associated to higher levels of IL-8 (16). 
Moreover, the resistance to sunitinib was associated with a higher microvessel density, 
indicating an escape from anti-angiogenesis mechanisms. Finally, the addition of 
monoclonal antibody anti-IL-8 resensitized the tumor to sunitinib activity. The conclusions 
of the Authors are that IL-8 mediates resistance to sunitinib and could represent a candidate 
target to reverse acquired or intrinsic resistance to sunitinib. 
Higher levels of IL-8 were associated with shorter progression free survival in mRCC 
patients treated in phase III trials of pazopanib (24). 
Some Authors also demonstrated in pre-clinical models that antiangiogenic drugs could 
elicit malignant progression of tumors with an increase of local invasion and distant 
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metastasis. In particular, it has been reported that short-term treatment with a potent 
inhibitor of tumor angiogenesis is able to induce an acceleration of metastasis formation 
(25). Moreover, other Authors reported that angiogenesis inhibitors targeting the VEGF 
pathway had antitumor effects in mouse models of pancreatic neuroendocrine carcinoma 
and glioblastoma, but concomitantly these drugs elicit tumor adaptation and progression to 
stages of greater malignancy, with heightened invasiveness and in some cases increased 
lymphatic and distant metastasis (26). Increased invasiveness is also seen by genetic ablation 
of the VEGF-A gene in both models, substantiating the results of the pharmacological 
inhibitors. The realization that potent angiogenesis inhibition can alter the natural history of 
tumors by increasing invasion and metastasis warrants clinical investigation, as the prospect 
has important implications for the development of enduring antiangiogenic therapies (26). 
Other two main mechanisms that could partially explain the ability of the tumor to become 
resistant to treatment are their capability to epithelial-mesenchimal transformation and the 
intra-tumoral heterogeneity.   
The epithelial to mesenchymal transition (EMT) process has been described in different 
neoplasms and associated with metastatic disease, drug resistance, and develop of 
angiogenesis (27-30). Treatment-associated tumor hypoxia has been reported to induce an 
EMT in several tumor models (31). How EMT as a mechanism of acquired resistance occurs 
in human tumors is unknown and deserves further investigation. In RCC, sarcomatoid 
phenotype is observed across all histological subtypes, and associated with a poorer 
prognosis and an increased resistance to VEGF inhibitors. A growing number of 
interdependent pathways have been linked to the induction of EMT, which, by definition, is 
a potentially transient/reversible phenotype of epithelial cancers. The reverted histologic 
phenotype observed in the xenografts also suggests that this escape mechanisms against 
anti-VEGF therapies may be transient (30, 32, 33).  
According to this hypothesis, patients who have initially received clinical benefit from 
treatment with TKIs and then developed resistant disease may respond again to TKIs 
following a break from anti-VEGF therapies. The “holiday” period from anti-VEGF 
therapies may lead to “reset” the tumor microenvironment and reestablish a primarily EGF 
driven tumor growth. This hypothesis is supported by anecdotic reports of patients who 
were treated with sunitinib with initial response and subsequent progression who 
responded again to sunitinib following different targeted therapies such as mTOR 
inhibitors. The apparent transient/reversible mechanism of resistance to anti-VEGF 
therapies may also explain why clinical benefit has been reported by sequencing different 
anti-VEGF therapies despite the fact that these agents target the same VEGF pathway. 
Regarding intratumoral heterogeneity, it has been demonstrated that mRCC, like other 
cancer, is characterized by a significant chromosomal instability that creates a selection of 
multiple clonal tumor subpopulations with an intrinsic multidrug resistance. Multiple 
intermixed cell subpopulations within one tumour differ by large genomic events as focal 
amplifications and deletions. For this reason, it is thought that single biopsy is often not 
representative of mutational landscape of the tumor (34). Recently have been developed 
methods able to study multiple subpopulations from different anatomic locations of 
neoplastic tissue (35). 
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 First line Second line 
Predictive 
factors 
Drug/Author N. Pts 
Type 
of therapy
N. of Pts 
(%)
 
Sunitinib 
Motzer et al,  
JCO 2009 
375 
(sunitinib arm) 
Anti-VEGF/ 
anti-mTOR 
182 
(56) 
- 
Beva + IFN 
Escudier et al, JCO 
2010 
325 
(bevacizumab-IFN 
arm) 
TKI 
180 
(55) 
- 
TKI* 
Vikers et al, 
Urology 2010 
645 
Anti-VEGF/ 
anti-mTOR 
216 
(30) 
Basal PS 
* Multi-institutional studies  
Abbreviations: PS: Performance status 
Table 1. Percentage of patients who access to a second line treatment after TKi in mRCC  
 
Setting  Author Drug % of incidence resistance 
1a line therapy 
Good-intermediate 
prognosis  
Motzer, 2007 
Ranpura, 2010* 
Sunitinib 22.4 
Su, 2010* Sorafenib 22.6 
1a line 
Poor prognosis 
Hudes 2007 Temsirolimus 33 
2a line therapy 
Motzer, 2008 Everolimus after TKI 20 
Ranpura, 2010* 
Sorafenib after 
Sunitinib 
33 
Su, 2010* 
Sunitinib after 
Sorafenib 
52.2 
*Meta-analysis 
Table 2. Percentage of patients with resistance according to the risk score and treatments in 
mRCC 
Due to this genomic instability, it is strongly believed that resistance is a dynamic 
mechanism changing in different conditions (treatment pressure, hypoxia pressure, etc) and 
during the tumor growth. This aspect could explain the response obtained in some patients 
re-challenged with sunitinib. It thought that during treatment interruption, the selective 
pressure from drugs is removed and drug-sensitive clones re-growth. Recently, Zama and 
colleagues reported the results of a retrospective study describing 5 partial response (22%) 
of 23 mRCC patients re-treated with sunitinib (36, 37). 
Also a “holiday” period from anti-VEGF therapies it is thought able to determine a 
reacquired drug-sensitivity by clones become resistant to TKI drugs. 
Various genes associated with resistance have been identified which could become a target 
for future treatments. Recently, Sanjmyatas and colleagues also reported a specific gene 
expression signature able to characterize the different metastatic potential in ccRCC (38). 
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It has been demonstrated that some genes are hyperexpressed when there is resistance, for 
example the gene which encodes sphingosine kinase, calvasculin, chemokine receptor 4 
(CXCR4), NNP1, arginase II, hypoxia-inducible protein-2 (HIG2) and VEGF. Other anti-
angiogenic genes, however, show reduced expression in resistant tumors, such as the genes 
which encode cytokines associated with interferon-gamma, in particular IP10 (CXCL10) and 
Mig (CXCL9) (39). Sphingosine-1-phosphate (S1P), a pleiotropic bioactive lipid derived from 
sphingosine through sphingosine kinase (SphK) action, is dysregulated in a variety of 
disease conditions including cancer. S1P is a tumorigenic and angiogenic growth factor 
produced normally by blood platelets, mast cells and possibly fibroblasts in the tumour 
microenvironment. It is capable of determining proliferation and migration of endothelial 
cells, favouring angiogenesis and tumour proliferation. Notably, several tumors up regulate 
the expression of SPHK1, which may greatly contribute to the putative increased levels of 
S1P. In experimental models it has been demonstrated that SphK and S1P expression was 
increased during sunitinib resistance (39).  
In xenografts models Bhatt and colleagues provided evidence that resistance to VEGF 
receptor therapy is due at least in part to resumption of angiogenesis in association with 
reduction of IFN┛-related angiostatic chemokines, and that this resistance can be delayed 
by restoration of angiostatic signalling with the concomitant administration of CXCL9 
(40). 
An emerging area of drug discovery called lipidomic-based therapeutics is in rapid develop. 
It directly targets pleiotropic bioactive lipids involved in cancer as well as other disorders. It 
has been postulated that S1P antibodies could represented a potential therapeutic strategies 
in the treatment of renal cancer (41). 
Other mechanisms, not completely known, sustaining secondary resistance in mRCC 
include: secondary mutations in tyrosine kinase receptors (analogous to EGFR TKI); 
recruitment of bone marrow-derived pro-angiogenic cells which can obviate the necessity 
of VEGF signalling, thereby affecting re-initiaton and continuance of tumour angiogenesis; 
increasing of pericyte coverage of the tumour vasculature, serving to support its integrity 
and attenuate the necessity for VEGF-mediated survival signalling has been described; 
activation and enhancement of invasion and metastasis to provide access to normal tissue 
vasculature without obligate neovascularisation (4).  
In table 3 are reported the main mechanisms of primary and secondary resistance in mRCC. 
3. How can we overcome resistance to anti-angiogenic agents? 
Many attempts have been made in the effort to overcome resistance to anti-VEGF 
treatments, but so far the results are disappointing. They include the use of non cross-
resistant drugs, integrating or combining current treatment, optimization of sequential 
therapies and TKI re-challenge. Finally, several ongoing studies are trying to clarify the 
optimal sequence of the different drugs and the significance of the rechallenge with TKI in 
the treatment strategies. 
As regards primary resistance, other than new experimental molecules the main route taken 
up until now has been to the combination of drugs for different biomolecular targets. 
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Primary resistance 
- Alternative pro-angiogenic pathways mediated by FGFR,
interleukin-8 (IL-8), insulin-like GFR, ephrins, and 
angiopoietins; 
- Non angiogenic mechanisms 
- Pre-existing inflammatory cell-mediated vascular protection 
(myeloid cell);  
- Hypovascularity status with consequent indifference toward 
angiogenesis inhibitors (desmoplastic stroma);  
- Co-option of normal vessels without requisite angiogenesis 
- Non clear cell histology 
Secondary resistance 
- New angiogenic wave induced by hypoxia determined by anti-
angiogenic drugs 
- Epithelial to mesenchymal transition 
- Intra-tumoral heterogeneity 
- Gene instability and gene iperexpression 
- Secondary mutations in tyrosine kinase receptors 
- Bone marrow-derived pro-angiogenic cells which can obviate the 
necessity of VEGF signalling; 
- Increasing of pericyte coverage of the tumour vasculature,
serving to support its integrity and attenuate the necessity for
VEGF-mediated survival; 
- Access to normal tissue vasculature without obligate
neovascularisation 
Note: to bibliographic references see the text 
Table 3. Main mechanisms of primary and secondary resistance in mRCC  
To overcome secondary resistance, various strategies are being explored: increasing the dose 
of the current drug, the use of non cross-resistant drugs (for example changing to a mTOR 
inhibitor such as everolimus after a anti-angiogenic drug), changing to another VEGF 
inhibitor (for example sunitinib after bevacizumab, or sorafenib after sunitinib, or axitinib 
after sorafenib), the use of a “drug holiday” (12, 42, 43). However, results obtained so far 
have been modest, above all because in general the choice of strategy has been empirical 
rather than determined by a strong biological rationale. It is therefore desirable that new 
studies are founded on convincing preclinical data. 
3.1 Drug combinations 
As previously mentioned, several studies using combinations of drugs targeted to different 
biomolecular targets have been started with the aim of increasing clinical activity. Many 
attempts have been made to verify if the combination of drugs with different mechanisms of 
action was able to improve the results of single agent therapy. Unfortunately, so far this 
strategy has given disappointing or negative results with a heavier profile of toxicity. 
Figure 1 shows the possible drug combination strategies in mCRC therapy. 
Some combinations have proved to be very toxic and relatively inactive and therefore they 
were quickly abandoned, as was the case of the combination of TKI and bevacizumab (44, 45). 
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Fig. 1. Possible strategies of drugs association in mRCC 
The high expression of EGFR in renal tumours from 50 to 90% (46), has also encouraged the 
use of anti-EGFR drugs in combination with anti-angiogenic agents. A study has recently been 
published by Motzer and colleagues at the Memorial Sloan-Kettering Cancer Center in New 
York in which gefitinib was combined with sunitinib in order to realise a double target. 
However, the reported results were similar to those obtained with sunitinib alone, but with an 
increase in toxicity. The Authors therefore discourage further studies on this combination (47). 
Another route which seems more promising is the combination of bevacizumab and m-TOR 
inhibitors. However, after some encouraging early experiences (48-50), more recent studies 
are re-dimensioning the preliminary results. Of particular note are the results of a 
randomized phase II trial which compared temsirolimus and bevacizumab vs sunitinib vs 
interferon alfa and bevacizumab (TORAVA study). Unfortunately, in view of clearly higher 
toxicity in the temsirolimus plus bevacizumab arm, superiority of this combination 
compared to other arms was not reported (51). The conclusions of Authors are that the 
toxicity of the temsirolimus and bevacizumab combination was much higher than 
anticipated and limited treatment continuation over time, whereas clinical activity was low 
compared with the benefit expected from sequential use of each targeted therapy. Thus, this 
combination cannot be recommended for first-line treatment in patients with mRCC. 
The combination of targeted drugs with immunological molecules such as interferon is 
proving to be more interesting. In particular, encouraging results have been reported on the 
combination of sorafenib and interferon alpha (52). 
 
Angiogenesis 
Tumoral 
proliferation 
Inhibitors of VEGF 
- sunitinib 
- sorafenib 
- axitinib 
- pazopanib 
- bevacizumab 
Inhibitors of mTOR/akt  
- temsirolimus 
-  everolimus 
-  perifosine 
Inhibitors of EGFR  
- erlotinib 
- gefitinib 
- lapatinib 
- cetuximab
Inhibitors of escape 
mecanisms  
- dovitinib 
- AMG 386 
- M200  
IFN 
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Generally speaking, even if it is necessary to wait for definitive results of ongoing phase III 
trials, the results reported so far do not encourage this therapeutic strategy. 
Table 4 shows the most significant experiences of the different drug combinations used.  
 
Drugs combinations/ 
Authors 
Setting 
 
N. of pts 
PFS 
(Mo) 
OR/SD Toxicity Notes 
Sorafenib + 
Interferone 
 
Gollob et al, JCO 2007 
 
phase II 
(1a e 2a 
line) 
40 10 
33% PR 
29% SD 
moderate 
50% pts in 2a 
line 
 
Good activity 
Beva + Sunitinib* 
 
Garcia et al, ASCO 2008 
phase I 
 
31 
(varius 
histology)
- 
3/7 mRCC 
1 /3 
melanoma 
1 surrene 
moderate Good activity 
Beva + Sorafenib 
 
Sosman et al, ASCO 2008
 
phase I-II
 
48 14 
25% PR 
18% SD 
high 
(hypertensi
on, 
stomatite, 
hand-foot 
sindrome) 
A negative 
experience 
Sunitinib + Gefitinib 
 
Motzer et al, AJCO 2010 
phase II 
 
42 11 
37% OR 
34% SD 
 
acceptable 
(diarrea 
G3-4 in 
14% of pts)
Activity 
similar to that 
of sunitinib 
alone 
Beva + Everolimus 
 
Whorf et al, ASCO ‘08 
Hainsworth, Whorf, JCO 
2010 
phase II 
1a e 2a 
lines 
80 
9,1 
7,1 
30/23% OR 
50/64% SD 
(1a/2a linea) 
moderate Good activity 
Beva + Temsirolimus 
 
Merchan et al, JCO 2009 
phae I-II 45 18/5.3 14,5% acceptable Long PFS 
Beva + Temsirolimus 
 vs Sunitinib 
 vs IFN + Beva 
 
Escudier et al, ASCO 
2010 
(TORAVA Trial) 
 
phase II R
Beva + 
Tem 
 8,2 
27,3% OR 
47,7% SD 
High 
(41% of pts  
stop 
therapy) 
Higher toxicity 
for 
experimental 
arm 
 
No confirmed 
results of 
phase II 
studies 
Sunitinib  8,2 
23,8% OR 
50% SD 
As 
aspected 
Beva + 
alpha IFN
 16,8 
39% OR 
34% SD 
As 
aspected 
Abbreviations: PFS: progression free survival. 
Table 4. Most significant experiences with drug combinations in mRCC 
3.2 New drugs and sequences 
Clearly, another approach to overcoming resistance mechanisms is the use of new molecules 
which have a more powerful anti-angiogenic activity or which are more directly aimed at 
the targets involved in resistance mechanisms. Axitinib and dovitinib are of particular 
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interest here. In preclinical trials, axitinib has shown much more powerful antiangiogenic 
activity than other TKIs (53, 54). Furthermore, interesting results have been reported in 
phase II studies as a second line therapy after sorafenib with an overall response of 23% and 
a stable disease of 55%; interestingly, the progression free survival was 7.4 months, one of 
the longest ever reported (42).  
Recently, beta FGFR has been identified as a new target for anti-angiogenic therapy. The 
system FGF/FGF receptor (FGFR) has been frequently reported as one of the most 
important escape pathways of anti-VEGFR therapies. It is involved in primary and 
secondary resistance mechanisms. The activation of FGFR3 is associated with cell 
proliferation and survival in certain cancer cell types. Thus, beta FGFR is proving to be a 
new interesting target for anti-angiogenic therapy. 
Dovitinib, a new small multi-target molecule, is able to strongly binds to FGFR3 and inhibits 
its phosphorylation, which may result in the inhibition of tumor cell proliferation and the 
induction of tumor cell death. In addition, this agent may inhibit other members of the TK 
receptors superfamily, including the VEGFR; FGFR1; PDGFR3; FMS-like tyrosine kinase 3; 
stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in 
an additional reduction in cellular proliferation and angiogenesis, and the induction of 
tumor cell apoptosis. A phase I/II has been recently concluded (55) and a large phase III 
clinical trial is ongoing to evaluate the efficacy of this drug as third line therapy in mRCC. 
Other drugs of great interest are the monoclonal antibody anti-S1P, a molecule directly 
involved in resistance mechanisms already being developed clinically, and the anti- IL-8 and 
anti-IL-12 antibodies, which are still being studied in preclinical trials. 
Regarding sequences, factors that could drive the choice of a more appropriate second line 
therapy are the response to primary treatment with TKI, the side effects reported in first line 
therapy, the patient risk score, and the histology of the tumor. 
At present, the use of non cross-resistant mTOR inhibitor everolimus is the only registered 
agent available as second line therapy for mRCC resistant to anti-angiogenic drugs. In fact, 
the registrative trial showed a significant benefit in terms of PFS of 4.9 months for 
everolimus vs 1.9 months for placebo (12).  
A second TKi as second line therapy is another option to consider for patients resistant to 
antiangiogenetic agents. Nevertheless, it is thought that this treatment must be propose only 
in carefully selected patients who did not show a rapid progression at the first line TKi. At 
present, this choice has a weaker recommendation because no definitive data from phase III 
studies are available yet.  
Notably, in the AVOREN study it has been reported a median overall survival of 23.3 
months for the sequence alfa interferone/bevacizumab followed by a second 
antiangiogenetic agent (TKI), with respect to only 21.3 months for the sequence alfa 
interferone/placebo followed by a TKI (7).  
Some Authors believe that better clinical outcomes are correlated with a higher number of 
lines of treatments used rather than with the sequences utilized. Consequently, they have 
hypothesize specific sequences with the aim to utilize the maximum of therapeutic options 
available. Others suppose that the sequence TKI-TKI is to prefer to that with TKI-mTORi on 
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the basis of some preliminary experiences. Also the rechallenge with the same drug has been 
proposed, especially when a “holiday” period from anti-VEGF therapies  is given to the 
patient. This break could be able to determine a reacquired drug-sensitivity by clones 
become resistant to TKI. Nevertheless, at present the majority of data are from small and 
retrospective studies regarding selected patients (36,37,56-61).  
Recently, the results of the phase III study with Axitinib as second line therapy have been 
published (62). Axitinib resulted in significantly longer PFS compared with sorafenib. 
Nevertheless,  in the subgroup of the patients treated previously with the TKI inhibitor the PFS 
was similar to what has been reported for the mTOR inhibitor everolimus (4.8 vs. 4.9 months). 
Of course, further controlled studies are needed to determine the real effect of prior anti-
angiogenesis therapy on the development of resistance to further therapies. A series of 
planned trials are evaluating what are the best sequences and timing.  
4. Conclusions 
The adoption of alternative angiogenic signaling pathways to compensate for inhibition of 
VEGF/VEGFR-mediated signaling seems to be the common mechanism for the 
development of cancer resistance to VEGF pathway inhibitors. Nevertheless, until now very 
few data are known about which alternative pathways are involved in resistant disease.   
Many attempts have been proposed to overcome resistance. These include the use of non 
cross-resistant drugs, the optimization of sequential therapies, and the use of combined 
therapies. Unfortunately, all these approaches have given only modest results. Therefore, 
the overcome resistance mechanisms to antiangiogenic agents remains the next challenge  in 
the treatment of renal cell carcinoma. 
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